ClinicalTrials.gg
Biological

GI-4000 clinical trials

Also written GI-4000.

studies test it
18
open now
0
in phase 3
0
first study started
2008

How each study uses GI-4000 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

GI-4000
18

Studies by the year they started

18 studies that test it; most in 2018 (9)

Studies that test GI-4000, by start year
YearStudies
20081
20101
20177
20189

By phase

A phase 1/2 study counts in both.

Phase 1
13
Phase 2
18

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 17 · Other 1

ImmunityBio, Inc. (16) · GlobeImmune (1) · Georgetown University (1)

Often tested with

Tested in the same studies.

Nogapendekin alfa inbakicept (16) · ETBX-011 (15) · ETBX-051 (13) · ETBX-061 (13) · GI-6301 (13) · Yeast-CEA vaccine (11) · ETBX-021 (8) · Bevacizumab (1)

Studies

Open first, then newest update. How each study uses GI-4000 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 18

Given beside what is tested · 1 — GI-4000 is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with GI-4000